Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Alumis
Biotech
Activist investor fails to derail Alumis' Acelyrin merger
Acelyrin’s shareholders have decided to power ahead with the merger despite the best efforts of an activist investor to sink the deal.
James Waldron
May 14, 2025 7:45am
Investor pressures Acelyrin to exit Alumis merger and liquidate
Apr 30, 2025 10:30am
Kaken pens $180M pact for Alumis' lead TYK2 inhibitor in Japan
Mar 25, 2025 6:55am
Acelyrin turns down surprise Concentra buyout offer
Mar 4, 2025 10:26am
